Latest Pharma Insights
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
FDA Discussion Paper Weighs Benefit-Risk For Autonomous And Remote Surgical Robots
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
FDA Discussion Paper Weighs Benefit-Risk For Autonomous And Remote Surgical Robots
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
NAD Backs Dove’s 24-Hour Moisture Claims, Rejects P&G Challenge Of Study Design
The National Advertising Division determined that Unilever's claims for Dove Deep Moisture Body Wash were substantiated by a core study, despite competitor Procter & Gamble's position that the study was flawed.
HBW Insight - November 9, 2026
The National Advertising Division determined that Unilever's claims for Dove Deep Moisture Body Wash were substantiated by a core study, despite competitor Procter & Gamble's position that the study was flawed.
HBW Insight - November 9, 2026
Consumer Health Advisory: Misleading Claims Under The Spotlight
What’s happening, why it matters and what’s next in US consumer health: Carpe pulled up for price claims, oral rinse claims pulled and firm found using additive banned half a century ago.
HBW Insight - November 9, 2026
What’s happening, why it matters and what’s next in US consumer health: Carpe pulled up for price claims, oral rinse claims pulled and firm found using additive banned half a century ago.
HBW Insight - November 9, 2026
Swiss Fines And Seizure Orders Warn Longevity Sellers Injectable NAD+ Is Not A Supplement
Swissmedic has imposed fines of up to CHF20,000 and ordered confiscation of up to CHF40,000 in unlawful gains over injectable NAD+ sold as a longevity treatment, saying injection, not marketing, makes a product a medicine.
HBW Insight - November 9, 2026
Swissmedic has imposed fines of up to CHF20,000 and ordered confiscation of up to CHF40,000 in unlawful gains over injectable NAD+ sold as a longevity treatment, saying injection, not marketing, makes a product a medicine.
HBW Insight - November 9, 2026
Over The Counter: Earning The Pharmacist’s Recommendation, With Thorrun Govind
Pharmacist, healthcare lawyer and broadcaster Thorrun Govind tells HBW Insight what consumer health companies can do to earn pharmacists’ trust and recommendations at the counter, as pharmacy teams face growing time and financial pressure.
HBW Insight - November 9, 2026
Pharmacist, healthcare lawyer and broadcaster Thorrun Govind tells HBW Insight what consumer health companies can do to earn pharmacists’ trust and recommendations at the counter, as pharmacy teams face growing time and financial pressure.
HBW Insight - November 9, 2026
Estée Lauder Reveals Skin Longevity Platform, L’Occitane Sells Elemis; Beauty Biz Roundup
Estée Lauder unveils Mastering Skin Longevity innovation platform at the China International Import Expo, as PAI Partners announces plan to buy British skin care brand ELEMIS from L’OCCITANE. Coty and e.l.f. Beauty report quarterly sales; Beauty Biz Roundup.
HBW Insight - November 9, 2026
Estée Lauder unveils Mastering Skin Longevity innovation platform at the China International Import Expo, as PAI Partners announces plan to buy British skin care brand ELEMIS from L’OCCITANE. Coty and e.l.f. Beauty report quarterly sales; Beauty Biz Roundup.
HBW Insight - November 9, 2026
Hikma Chief Cites Success In Stabilizing Generics And Injectables
Referring to 2026 as an “investment, transition and stabilization year,” Hikma CEO Said Darwazah suggested that stability had returned to the company as it offered a third-quarter trading update that forecasted flat 2026 sales for generics and injectables.
Generics Bulletin - November 9, 2026
Referring to 2026 as an “investment, transition and stabilization year,” Hikma CEO Said Darwazah suggested that stability had returned to the company as it offered a third-quarter trading update that forecasted flat 2026 sales for generics and injectables.
Generics Bulletin - November 9, 2026
Sandoz Makes First Semaglutide Launch With Adalvo In Brazil
Sandoz has opened up a major new frontier for its generics business with the launch of its first semaglutide product, in Brazil – where the Adalvo-partnered Owozy version will be marketed by Biolab & Co.
Generics Bulletin - November 9, 2026
Sandoz has opened up a major new frontier for its generics business with the launch of its first semaglutide product, in Brazil – where the Adalvo-partnered Owozy version will be marketed by Biolab & Co.
Generics Bulletin - November 9, 2026
Deals Shaping The Industry, Sep 2026
An interactive look at pharma and medtech deals made during September 2026. Data courtesy of Biomedtracker.
In Vivo - November 9, 2026
An interactive look at pharma and medtech deals made during September 2026. Data courtesy of Biomedtracker.
In Vivo - November 9, 2026